FDA Center for Drug Evaluation & Research Issues Warning Letter to NOVARX
June 17, 2026
June 17, 2026
WASHINGTON, June 17 -- The U.S. Department of Health and Human Services Food and Drug Administration issued the following warning letter to Nova Vascular LLC dba NOVARX from its Center for Drug Evaluation and Research:
* * *
Recipient: Nova Vascular LLC dba NOVARX, 99 Wall Street, #878, New York, NY 10005, United States, info@novarx.com
Issuing Office: Center for Drug Evaluation and Research (CDER), United States
WARNING LETTER
Ref . . .
* * *
Recipient: Nova Vascular LLC dba NOVARX, 99 Wall Street, #878, New York, NY 10005, United States, info@novarx.com
Issuing Office: Center for Drug Evaluation and Research (CDER), United States
WARNING LETTER
Ref . . .